

DAFTAR PUSTAKA

- Akarapatima, K., Chang, A., Prateepchaiboon, T., Pungpipattrakul, N., Songjamrat, A., *et al.* 2022. Comparison of Overall Survival between Transarterial Chemoembolization and Best Supportive Care in Intermediate-Stage Hepatocellular Carcinoma. *Asian Pacific journal of cancer prevention: APJCP*, 23(9), 3173–3178. <https://doi.org/10.31557/APJCP.2022.23.9.3173>
- Amalia, A., Latief, N., Murtala, B., Zainuddin, A.A. & Daud, N.A.S., 2020. Factors affecting tumor response to transarterial chemoembolization (TACE) therapy in patients with hepatocellular carcinoma (HCC). *Journal of the Medical Sciences (Berkala Ilmu Kedokteran)*, 52(2), pp.144–152. doi:10.19106/JMedSci005202202006
- Arrè, V., Negro, R., & Giannelli, G., 2025, . The role of inflammasomes in hepatocellular carcinoma: Mechanisms and therapeutic insights. In *Annals of Hepatology* (Vol. 30, Issue 1). Elsevier Espana S.L.U. <https://doi.org/10.1016/j.aohep.2024.101772>
- Balta, S. dan Ozturk, C. 2015. The platelet-lymphocyte ratio: A simple, inexpensive and rapid prognostic marker for cardiovascular events. *Platelets*, 26(7), 680–681. <https://doi.org/10.3109/09537104.2014.979340>
- Brar, G., Greten, TF., Graubard, BI., McNeel, TS., Petrick, JL., McGlynn, KA. 2020. Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis. *Hepatology Communications*, Vol. 4. <https://doi.org/10.1002/hep4.1564>
- Brar, G., Kesselman, A., Malhotra, A., & Shah, M. A. (2021). Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. In *JCO Oncol Pract* (Vol. 18). <https://doi.org/10.>
- Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of

- incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 74(3), 229–263. <https://doi.org/10.3322/caac.21834>
- Cammà, C., dan Cabibbo, G. 2009. Prognostic scores for hepatocellular carcinoma: none is the winner. *Liver international : official journal of the International Association for the Study of the Liver*, 29(4), 478–480. <https://doi.org/10.1111/j.1478-3231.2009.01994.x>
- Chan SL, Wong AM, Lee K, et al. Prognostic and Predictive Role of Alpha-Fetoprotein in Hepatocellular Carcinoma: A Contemporary Review. *Cancers*. 2022;14(3):597. <https://www.mdpi.com/2072-6694/14/3/597>
- Dorn, D. P., Bryant, M. K., Zarzour, J., Smith, J. K., Redden, D. T., Saddekni, S., et al. 2014. Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function. *HPB : the official journal of the International Hepato Pancreato Biliary Association*, 16(7), 648–655. <https://doi.org/10.1111/hpb.12194>
- El-Fattah, MA., Aboelmagd, M., Elhamouly, M. 2017. Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study. *United European Gastroenterology Journal* 5(2). <https://doi.org/10.1177/2050640616659024>
- El-Serag, H. B. dan Rudolph, K. L. 2007. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* 132, 2557–2576, <https://doi.org/10.1053/j.gastro.2007.04.061>
- European Association For The Study Of The Liver dan European Organisation For Research And Treatment Of Cancer. 2012. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *Journal of hepatology*, 56(4), 908–943. <https://doi.org/10.1016/j.jhep.2011.12.001>
- Ferlay J et al. (2024b). *Statistics at a glance, 2022 Top 5 most frequent cancers*. <https://gco.iarc.who.int/today>,
- Fu, H., Wang, Y., & Xiang, B. (2025). Pan-Immune-Inflammation Value as a

Prognostic Biomarker for Hepatocellular Carcinoma Patients Undergoing Hepatectomy. *Journal of Inflammation Research, Volume 18*, 6411–6425. <https://doi.org/10.2147/JIR.S521603>

- Ghouri, Y. A., Mian, I., dan Rowe, J. H. 2017. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. *Journal of carcinogenesis*, 16, 1. https://doi.org/10.4103/jcar.JCar_9_16
- Gray, S. H., White, J. A., Li, P., Kilgore, M. L., Redden, D. T., Abdel Aal, A. K., *et al.* 2017. A SEER Database Analysis of the Survival Advantage of Transarterial Chemoembolization for Hepatocellular Carcinoma: An Underutilized Therapy. *Journal of vascular and interventional radiology : JVIR*, 28(2), 231–237.e2. <https://doi.org/10.1016/j.jvir.2016.09.022>
- Guo, H., Wu, T., Lu, Q., Dong, J., Ren, Y. F., Nan, K. J., Lv, Y., & Zhang, X. F. (2017). Hepatocellular carcinoma in elderly: Clinical characteristics, treatments and outcomes compared with younger adults. *PLoS ONE*, 12(9). <https://doi.org/10.1371/journal.pone.0184160>
- Hsu, CY., Lee, YH., Hsia, CY., Huang, YH., Su, CW., 2013. Performance Status in Patients With Hepatocellular Carcinoma: Determinants, Prognostic Impact, and Ability to Improve the Barcelona Clinic Liver Cancer System. *HEPATOLOGY*, Vol. 57, No. 1. <https://doi.org/10.1002/hep.25950>
- Huang, X. Z., Chen, W. J., Zhang, X., Wu, C. C., Zhang, C. Y., Sun, S. S., *et al.* 2017. An Elevated Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Colorectal Cancer: A Meta- Analysis. *Disease markers*, 2017,1053125. <https://doi.org/10.1155/2017/1053125>
- Hung, Y. W., Lee, I. C., Chi, C. T., Lee, R. C., Liu, C. A., Chiu, N. C., *et al.* 2021. Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria. *Liver Cancer*. <https://doi.org/10.1159/000517393>

- Indreswara, D.R., Maimunah, U. & Retnowati, E., 2022. Serum AFP (Alpha Fetoprotein) levels profile of hepatocellular carcinoma patients in Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. *Medical Journal of Indonesia*, [online] Available at: <https://e-journal.unair.ac.id/MBIO/article/view/29123> [Accessed 12 Nov. 2025].
- Kaibori, M., Yoshii, K., Yokota, I., Hasegawa, K., Nagashima, F., Kubo, S. 2017. Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma. *Annals of Surgery* Volume 20, No. 20. <https://doi:10.1097/SLA.0000000000002526>
- Kanneganti, M., Al-Hasan, M., Bourque, S., Deodhar, S., Yang, J. D., Huang, D. Q., Kulkarni, A. V., Gopal, P., Parikh, N. D., Kanwal, F., Patel, M. S., & Singal, A. G. (2024). Older Age But Not Comorbidity is Associated with Worse Survival in Patients with Hepatocellular Carcinoma. *Clinical Gastroenterology and Hepatology*. <https://doi.org/10.1016/j.cgh.2024.10.015>
- Kim J, Kim JH, Ko E, et al. *Model Predicting Survival in Intermediate-Stage HCC Patients Reclassified for TACE Based on the 2022 BCLC Criteria*. *Cancers*. 2023;17(5):894.
- Kinoshita, A., Onoda, H., Imai, N., Iwaku, A., Oishi, M., Fushiya, N., et al. 2012. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. *British journal of cancer*, 107(6), 988– 993. <https://doi.org/10.1038/bjc.2012.354>
- Kong, J., et al., 2018. Transarterial chemoembolization for advanced hepatocellular carcinoma: A retrospective study. **Oncology Letters**, 15(6), pp.8591–8598.
- Konsensus Terapi Sistemik Karsinoma Sel Hati Di Indonesia Perhimpunan Peneliti Hati Indonesia PPHI 2021. (N.D.)

- Kudo, M., Han, K. H., Ye, S. L., Zhou, J., Huang, Y. H., Lin, S. M., *et al.* 2020. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. *Liver cancer*, 9(3), 245–260. <https://doi.org/10.1159/000507370>
- Lanza, C., Ascenti, V., Amato, G.V., *et al.*, 2023. All you need to know about TACE: A comprehensive review of indications, techniques, efficacy, limits, and technical advancement. **Journal of Clinical Medicine**, 14(2), p.314. Available at: <https://www.mdpi.com/2077-0383/14/2/314>
- Liang, X., Bu, J., Jiang, Y., Zhu, S., Ye, Q., Deng, Y., Lu, W., & Liu, Q. (2024). Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment. *International Journal of Hyperthermia*, 41(1). <https://doi.org/10.1080/02656736.2024.2355279>
- Liaw, F. Y., Huang, C. F., Chen, W. L., Wu, L. W., Peng, T. C., Chang, Y. W., *et al.* 2017. Higher Platelet-to-Lymphocyte Ratio Increased the Risk of Sarcopenia in the Community-Dwelling Older Adults. *Scientific reports*, 7(1), 16609. <https://doi.org/10.1038/s41598-017-16924-y>
- Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., *et al.* 2021. Hepatocellular carcinoma. *Nature reviews. Disease primers*, 7(1), 6. <https://doi.org/10.1038/s41572-020-00240-3>
- Lopes, FdLM., Coelho, FF., Kruger, JAP., Fonseca, GM., Araujo, RLCd., Jeismann, VB. 2016. Influence of Hepatocellular Carcinoma Etiology in the survival After resection. *ABCD Arq Bras Cir Dig* ;29(2):105-108. <https://doi.org/10.1590/0102-6720201600020010>
- Ma, W., Zhang, P., Qi, J., Gu, L., Zang, M., Yao, H., *et al.* 2016. Prognostic value of platelet to lymphocyte ratio in hepatocellular carcinoma: A meta-analysis. *Scientific Reports*, 6, 16–18. <https://doi.org/10.1038/srep35378>

- Mahassadi, A. K., Anzouan-Kacou Kissi, H., dan Attia, A. K. 2021. The Prognostic Values of Neutrophil-to-lymphocyte Ratio and Platelet-to-Lymphocyte Ratio at Baseline in Predicting the In-hospital Mortality in Black African Patients with Advanced Hepatocellular Carcinoma in Palliative Treatment: A Comparative Cohort Study. *Hepatic medicine : evidence and research*, 13, 123–134. <https://doi.org/10.2147/HMER.S333980>
- Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., *et al.* 2018. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology (Baltimore, Md.)*, 68(2), 723–750. <https://doi.org/10.1002/hep.29913>
- Matsuzaki, K., Murata, M., Yoshida, K., Sekimoto, G., Uemura, Y., Sakaida, N., *et al.* 2007. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. *Hepatology (Baltimore, Md.)*, 46(1), 48–57. <https://doi.org/10.1002/hep.21672>
- Mazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., *et al.* 2009. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. *The Lancet. Oncology*, 10(1), 35–43. [https://doi.org/10.1016/S1470-2045\(08\)70284-5](https://doi.org/10.1016/S1470-2045(08)70284-5)
- McGlynn, K. A., Petrick, J. L., & El-Serag, H. B. (2021). Epidemiology of Hepatocellular Carcinoma. In *Hepatology* (Vol. 73, Issue S1, pp. 4–13). John Wiley and Sons Inc. <https://doi.org/10.1002/hep.31288>
- McMillan DC. 2009. Systemic inflammation, nutritional status and survival in patients with cancer. *Curr Opin Clin Nutr Metab Care*, 2009;12:223-6.

- Meng, X., Wei, G., Chang, Q., Peng, R., Shi, G., Zheng, P., *et al.* 2016. The platelet- to-lymphocyte ratio, superior to the neutrophil-to-lymphocyte ratio, correlates with hepatitis C virus infection. *International journal of infectious diseases : IJID: official publication of the International Society for Infectious Diseases*, 45, 72–77. <https://doi.org/10.1016/j.ijid.2016.02.025>
- Mirici-Cappa, F., Gramenzi, A., Santi, V., Zambruni, A., Di Micoli, A., Frigerio, M., *et al.* 2010. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. *Gut*, 59(3), 387–396. <https://doi.org/10.1136/gut.2009.194217>
- Müller, L., Stoehr1, F., Kunz, A. M., Hahn, F., Weinmann, A., Kloeckner, R. 2021. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. *Journal of Hepatocellular Carcinoma*: 8 403–419. <https://doi.org/10.2147/JHC.S28573>
- Nishikawa, H., Kita, R., Kimura, T., Ohara, Y., Takeda, H., Sakamoto, A., *et al.* 2014. Transcatheter arterial chemoembolization for intermediate-stage hepatocellular carcinoma: clinical outcome and safety in elderly patients. *Journal of Cancer*, 5(7), 590–597. <https://doi.org/10.7150/jca.9413>
- Noviyan, R., Ratnasari, N., dan Triwikatmani C. 2022. Analisis Kesintasan Pasien Karsinoma Sel Hati Yang Menjalani *Transarterial Chemoembolization* Berdasarkan Kriteria *Up To Seven*. (Tesis Subspesialis, Universitas Gadjah Mada). <https://etd.repository.ugm.ac.id/>
- Palumbo, J. S., Talmage, K. E., Massari, J. V., La Jeunesse, C. M., Flick, M. J., Kombrinck, K. W., *et al.* 2005. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. *Blood*, 105(1), 178–185. <https://doi.org/10.1182/blood-2004-06-2272>
- patients with hepatocellular carcinoma. *World Journal of Gastroenterology*, Vol. 10, No.11. <https://doi:10.3748/wjg.v10.i11.1547>
- Perhimpunan Peneliti Hati, 2021, Konsensus Terapi Sistemik Karsinoma Sel Hati Di Indonesia Perhimpunan Peneliti Hati Indonesia PPHI 2021

- Petrick, J. L., Florio, A. A., Znaor, A., Ruggieri, D., Laversanne, M., Alvarez, C. S., *et al.* 2020. International trends in hepatocellular carcinoma incidence, 1978- 2012. *International journal of cancer*, 147(2), 317–330. <https://doi.org/10.1002/ijc.32723>
- Pinter, M., Trauner, M., Peck-Radosavljevic, M., dan Sieghart, W. 2016. Cancer and liver cirrhosis: implications on prognosis and management. *ESMO open*, 1(2), e000042. <https://doi.org/10.1136/esmoopen-2016-000042>
- Plantureux, L., Mège, D., Crescence, L., Dignat-George, F., Dubois, C., dan Panicot- Dubois, L. 2018. Impacts of Cancer on Platelet Production, Activation and Education and Mechanisms of Cancer-Associated Thrombosis. *Cancers*, 10(11), 441. <https://doi.org/10.3390/cancers10110441>
- PPHI. 2017. Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati. Jakarta: Perhimpunan Peneliti Hati Indonesia.
- Raoul, JL., Forner, A., Bolondi, L., Cheung, TT., Kloeckner, R., de Baere, T. 2019. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. *Cancer Treatment Reviews* 72; 28–36. <https://doi.org/10.1016/j.ctrv.2018.11.002>
- Rebonato, A., Graziosi, L., Maiettini, D., Marino, E., De Angelis, V., Brunese, L., *et al.* 2017. Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. *Gastroenterology research and practice*, 2017, 4164130. <https://doi.org/10.1155/2017/4164130>
- Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., & Reig, M. (2025). EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. *Journal of Hepatology*, 82(2), 315–374. <https://doi.org/10.1016/j.jhep.2024.08.028>

- Scaffaro, L. A., Stella, S. F., Alvares-Da-Silva, M. R., dan Krueel, C. D. 2015. Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma. *World journal of hepatology*, 7(3), 628–632. <https://doi.org/10.4254/wjh.v7.i3.628>
- Silk, T., Silk, M., dan Wu, J. 2022. Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. *World journal of gastroenterology*, 28(23), 2561–2568. <https://doi.org/10.3748/wjg.v28.i23.2561>
- Stoiber, D dan Assinger, A. 2020. Platelet-Leukocyte Interplay in Cancer Development and Progression. *Cells*, 9(4):855. <https://doi.org/10.3390/cells9040855>
- Suresh, D., Srinivas, A. N., dan Kumar, D. P. 2020. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. *Frontiers in oncology*, 10, 601710. <https://doi.org/10.3389/fonc.2020.601710>
- Suzuki, K., Aiura, K., Ueda, M., dan Kitajima, M. 2004. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents. *Pancreas*, 29(2), 132–140. <https://doi.org/10.1097/00006676-200408000-00008>
- Szkandera, J., Gerger, A., Liegl-Atzwanger, B., Absenger, G., Stotz, M., Samonigg, H., *et al.* 2013. Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients. *British Journal of Cancer*, 109(9), 2316–2322. <https://doi.org/10.1038/bjc.2013.595>
- Tangkijvanich, P., Mahachai, V., Suwangool, P., Poovorawan, Y. 2004.
- Tian, X. C., Liu, X. L., Zeng, F. R., Chen, Z., dan Wu, D. H. 2016. Platelet-to-lymphocyte ratio acts as an independent risk factor for patients with hepatitis B virus-related hepatocellular carcinoma who received transarterial chemoembolization. *European review for medical and pharmacological sciences*, 20(11), 2302–2309.

- Tunissiolli, N. M., Castanhole-Nunes, M. M. U., Biselli-Chicote, P. M., Pavarino, E. C., da Silva, R. F., da Silva, R. D. C. M. A., Goloni-Bertollo, E. M. 2017. Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. *Asian Pacific Journal of Cancer Prevention*, Vol 18; 863-872. <https://doi:10.22034/APJCP.2017.18.4.863>
- Wada, Y., Nakashima, O., Kutami, R., Yamamoto, O. dan Kojiro, M. 1998. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. *Hepatology (Baltimore, Md.)* 27, 407–414. <https://doi.org/10.1002/hep.510270214>
- Wang, Y., Attar, B. M., Fuentes, H. E., Jaiswal, P., dan Tafur, A. J. 2017. Evaluation of the prognostic value of platelet to lymphocyte ratio in patients with hepatocellular carcinoma. *Journal of Gastrointestinal Oncology*, 8(6), 1065– 1071. <https://doi.org/10.21037/jgo.2017.09.06>
- Wei, Y., Mao, D., Liu, T., Wu, W., Yang, Z. and Liu, X., 2025. The predictive value of PIV, PLR, LMR, NPR, and NLR for the prognosis of transarterial chemoembolization in patients with hepatocellular carcinoma combined with liver cirrhosis. *BMC Gastroenterology*, 25(315). Available at: <https://doi.org/10.1186/s12876-025-03815-0>
- White, J. A., Redden, D. T., Bryant, M. K., Dorn, D., Saddekni, S., Abdel Aal, A. K., *et al.* 2014. Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. *HPB : the official journal of the International Hepato Pancreato Biliary Association*, 16(12), 1095–1101. <https://doi.org/10.1111/hpb.12313>
- Xue, T. C., Jia, Q. A., Ge, N. L., Zhang, B. H., Wang, Y. H., Ren, Z. G., *et al.* 2015. The platelet-to-lymphocyte ratio predicts poor survival in patients with huge hepatocellular carcinoma that received transarterial chemoembolization. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*, 36(8), 6045–6051. <https://doi.org/10.1007/s13277-015-3281-x>

- Yang, Y., Wang, M. C., Tian, T., Huang, J., Yuan, S. X., Liu, L., *et al.* 2020. A High Preoperative Platelet-Lymphocyte Ratio Is a Negative Predictor of Survival After Liver Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Study. *Frontiers in oncology*, 10, 576205. <https://doi.org/10.3389/fonc.2020.576205>
- Yasui, Y., Shima, T., Kobayashi, N., Sato, T., Uojima, H., Terashima, T., Arai, K., *et al.*, 2017. Up-to-seven criteria as a useful predictor for tumor downstaging and survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *Cancers*, 11(3), p.405. available at: <https://www.mdpi.com/2072-6694/11/3/405>
- Yasui, Y., Tsuchiya, K., Kurosaki, M., Takeguchi, T., Takeguchi, Y., Okada, M., *et al.* 2017. Up-to-seven criteria as a useful Predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after the initial conventional TACE: Predictive value of up-to-seven criteria. *Hepatology Research* 48(6). <https://doi:10.1111/hepr.13048>
- Yeh, S.-H. & Chen, P.-J., 2010. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. *Oncology*, 78(Suppl. 1), pp.172–179. doi:10.1159/000315247.
- Yu, Y., Wang, Y., Zhang, X., Li, J. and Chen, Y., 2023. Prognostic significance of the pretreatment pan-immune-inflammation value in cancer patients: An updated meta-analysis of 30 studies. *Frontiers in Nutrition*, 10, p.1259929.
- Zhang, L., Hong, W., Wang, Z., Zheng, C., Liang, B., dan Shi, H. 2023. Safety and Effectiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Aged Greater versus Less Than 80 Years. *Clinical interventions in aging*, 18, 1883–1892. <https://doi.org/10.2147/CIA.S429259>
- Zhang, Y. J., Chen, M. S., Chen, Y., Lau, W. Y., & Peng, Z. 2021. Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma. *JAMA network open*, 4(9),

e2126992. <https://doi.org/10.1001/jamanetworkopen.2021.26992>

Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., *et al.* 2020. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). *Liver cancer*, 9(6), 682–720. <https://doi.org/10.1159/000509424>

Zhu, Y., Wang, E., Zhao, S., *et al.*, 2023. Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study. *Frontiers in Oncology*, 12. doi:10.3389/fonc.2022.98355